Effect of intrapulmonary injection of processed serum derived from covid-19 patients in reduction of pulmonary complications

Effect of intratracheal Injection of Processed Autologous Serum Derived from Patients with covid-19 in oxygenation parameters and pulmonary Complications

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20091012002582N21

Enrollment

Registered

2020-05-18

Start date

2019-05-05

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: After taking blood samples and centrifugation with 5000/min the plasma will be separated and incubated for 8 hours and then this plasma will be injected intratrache

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: intubated covid-19 patients

Exclusion criteria

Exclusion criteria: transplantation history malignancy thoracic surgery active bacterial infection autoimmune disease

Design outcomes

Primary

Measure	Time frame
Oxygenation. Timepoint: During 10 days from intratracheal injection. Method of measurement: Arterial blood gas analysis.	—

Secondary

Measure	Time frame
Change in CO2. Timepoint: During 10 days after intratracheal intubation. Method of measurement: Analysis of arterial blood gases.;Respiratory compliance. Timepoint: During 10 days after intratracheal intubation. Method of measurement: Ventilator.;Airway resistance. Timepoint: During 10 days after intratracheal intubation. Method of measurement: Ventilator.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Roshangar

Tabriz University of Medical Sciences

lroshangar@yahoo.com+98 41 3334 2086

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026